
Marijuana may make sleep worse, especially for regular users, study finds
It's a common assumption among marijuana users: Using weed will help you fall asleep and stay asleep. Scientists, however, aren't so sure that's true.
'This is an understudied but important area, as many people are increasingly turning to cannabis products as sleep aids,' said sleep specialist Wendy Troxel, a senior behavioral scientist at RAND Corporation, who was not involved in the study.
'But we really lack solid evidence demonstrating whether cannabis helps or hurts sleep,' Troxel added.
Use of weed may actually harm sleep, a new study has found. The research, published Monday in a BMJ journal, revealed adults who use weed 20 or more days during the last month were 64% more likely to sleep less than six hours a night and 76% more likely to sleep longer than nine hours a night.
Optimal sleep for adults is defined by the US Centers for Disease Control and Prevention as seven to eight hours a night.
Moderate consumption -- using weed less than 20 days during the past month -- didn't create short sleep problems, but people were 47% more likely to snooze nine or more hours a night, the study also found.
Why is short and long sleep a problem?
'Large population-based studies show that both short sleep and long sleep are associated with an increased risk of heart attacks and strokes, as well as the long-term progression of things like atherosclerosis, diabetes, coronary artery disease and any of the major cardiovascular diseases,' said lead study author Calvin Diep, who is resident in the department of anesthesiology and pain medicine at the University of Toronto.
'It seems with sleep there's kind of this 'Goldilocks phenomenon' where there's an amount that 'just right,'' Diep said.
One in three Americans don't get enough sleep, according to the CDC. In addition, 50 million to 70 million Americans struggle with sleep disorders such as sleep apnea, insomnia and restless leg syndrome, which can ruin a good night's shut-eye.
The CDC calls that a 'public health problem,' because disrupted sleep is associated with a higher risk of conditions including high blood pressure, weakened immune performance, weight gain, a lack of libido, mood swings, paranoia, depression, and a higher risk of diabetes, stroke, cardiovascular disease, dementia and some cancers.
NO CLEAR EVIDENCE EITHER WAY
The study analyzed use of marijuana for sleep among 21,729 adults between the ages of 20 and 59. The data was gathered by the National Health and Nutrition Examination Survey, and is considered representative of over 146 million Americans.
In addition to issues with short and long sleep, people in the study who used weed within the last 30 days were also more likely to say they have trouble falling asleep or staying asleep, and were more likely to say they have discussed sleep problems with a health care provider, Diep said.
'The problem with our study is that we can't really say that it's causal, meaning we can't know for sure whether this was simply individuals who were having difficulty sleeping, and that's why they use the cannabis or the cannabis caused it,' he added.
Prior studies have also found a connection between the two components of marijuana, CBD and THC, and poor sleep. CBD, or cannabidiol, is a key component of medical marijuana, while THC, or tetrahydrocannabinol, is the main psychoactive compound in cannabis that produces the high sensation.
A 2018 randomized, double-blind, placebo-controlled study -- the gold standard -- found no benefit from CBD on sleep in healthy volunteers. Other studies have also found high rates of insomnia when withdrawing from nightly use of marijuana.
'At this time there still isn't any clear evidence that cannabis is helping sleep,' said Dr. Bhanu Prakash Kolla, a sleep medicine specialist in the Center for Sleep Medicine at the Mayo Clinic in Rochester, Minnesota, who was not involved in any of the studies.
'We know that when people initiate use there is some benefit in the immediate short term but there is quick tolerance to this effect,' Kolla said. " There currently is no good quality evidence to suggest that cannabis will help improve sleep quality or duration."
CONFOUNDING FACTORS
Still, people continue to believe that weed is helping their sleep. Surveys of marijuana users show they do indeed rely on the drug for better sleep.
'The issue is that there's a disconnect between these anecdotal reports of people reporting therapeutic benefits and the evidence behind it in terms of the data,' Diep said.
One possible reason, Kolla said, is that when people stop using cannabis after a period of regular use, the withdrawal effects from weed can cause sleep disruptions. That leads people to believe 'the cannabis was in fact helping (sleep), while what they are actually experiencing are withdrawal symptoms.'
Another factor to consider is the increased potency of weed today as compared to when many of the studies on cannabis and sleep were conducted, said Dr. Karim Ladha, staff anesthesiologist and clinician-scientist in the department of anesthesiology and pain medicine at the University of Toronto.
'A lot of the older data related to cannabis is based on lower doses of THC than what patients are using now, and there's very little research related to CBD,' Ladha said.
'Studies tell us about what happens at a population level, but on an individual level that discussion is much more personal,' he said. 'The studies just give us the possibilities that (marijuana) could hurt your sleep, but it may help and so we just don't know until you try it."
That's why additional studies need to be done, he added.
'Patients are spending money and time and resources to obtain cannabis right now to help with sleep,' Ladha said. 'I think as the medical community, we need to do everything we can to make sure that we enable our patients to make the best possible decisions for their health.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
10 minutes ago
- National Post
WELL Health to Announce Second Quarter 2025 Financial Results on August 14, 2025
Article content VANCOUVER, British Columbia — WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ('WELL' or the 'Company'), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that the Company will release its Fiscal Second Quarter 2025 financial results for the period ended June 30, 2025, before the market opens on Thursday, August 14, 2025. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at 1:00 pm ET (10:00 am PT). The call will be hosted by Hamed Shahbazi, Chairman and Chief Executive Officer and Eva Fong, Chief Financial Officer. Please dial in 10 minutes prior to the start of the call. Article content Conference Call Participant Details Article content Date: Thursday, August 14, 2025 Article content Time: 1:00 PM ET / 10:00 AM PT Article content International Toll: 289-514-5100 Article content North American Toll Free: 1-800-717-1738 Article content To attend the webcast, register now or visit for details. Article content WELL HEALTH TECHNOLOGIES CORP. Article content Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director WELL Health Technologies Corp. Article content About WELL Health Technologies Corp. Article content WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States, WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: Article content Article content Article content Article content Contacts Article content Article content Article content Article content

National Post
10 minutes ago
- National Post
Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC
Article content Company highlights expanded capabilities following Akoya Biosciences Acquisition and Simoa ® technology included in more than 55 posters and oral presentations at the annual conference demonstrating its impact on neurodegenerative disease research Article content BILLERICA, Mass. — Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commercial launch of two novel phospho-tau assays: p‑Tau 205 and p‑Tau 212, expanding its market-leading portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The announcement comes alongside Quanterix's robust presence at the Alzheimer's Association International Conference (AAIC) 2025, with more than 55 posters and presentations featuring data generated using its Simoa ® technology. Article content These new assays enable the precise detection of tau phosphorylation sites, biomarkers increasingly associated with early and progressive stages of Alzheimer's disease. Developed on Quanterix's ultra-sensitive Simoa ® platform, our p‑Tau 205 and 212 assays empower researchers to explore novel disease mechanisms, refine patient stratification, and support therapeutic development through fluid-based biomarkers. Article content Quanterix's growing leadership in neurobiology was further reinforced by its recent acquisition of Akoya Biosciences, bringing advanced spatial proteomics into its scientific ecosystem. The Human FFPE Neurobiology Panel, originally developed by Akoya, complements the Simoa ® platform by enabling high-plex, spatially resolved analysis of disease-specific protein expression in brain tissue. Together, these platforms offer researchers a powerful combination of tissue- and fluid-based biomarker discovery to accelerate translation from bench to bedside. Article content 'The addition of p‑Tau 205 and 212 strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding, and more personalized treatment approaches for Alzheimer's,' said Masoud Toloue, PhD, CEO of Quanterix. 'Combined with the recent integration of Akoya's spatial biology platform, we are now uniquely positioned to offer researchers a multi-dimensional view of pathobiology—bridging the gap between soluble protein dynamics and spatial tissue context. By uniting two best-in-class technologies, we're advancing the future of precision diagnostics across neurology, oncology, and immunology.' Article content The newly launched p-Tau 205 and p-Tau 212 assays are now available to customers for use on the HD-X or SR-X instruments or testing directly through Quanterix's in-house Accelerator Lab, a CLIA-licensed, ISO 15189-accredited facility providing contract biomarker testing services to global partners in pharma, biotech, and academia. Article content To learn more about the new assays or Quanterix's expanded capabilities, visit or stop by the Quanterix booth at AAIC 2025. Article content About Quanterix Article content Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at Article content Article content Article content Article content Contacts Article content Media Contact: Marissa Klaassen (781) 913.8036 media@ Article content


CBC
41 minutes ago
- CBC
GTA could feel like over 40 C on Monday as heat warning continues: Environment Canada
Much of the Greater Toronto Area remains under a heat warning on Monday that is expected to end on Tuesday night, according to Environment Canada. The federal weather agency first issued a heat warning on Sunday, but said the hottest conditions are expected on Monday and Tuesday. The region is expected to see daytime high temperatures between 30 to 33 C on Monday, Environment Canada said. With humidity, temperatures could feel like between 38 to 43 C. Nighttime lows are expected between 19 to 21 C, which Environment Canada said will provide little relief from the heat. "Confidence has increased that cooler temperatures will arrive on Wednesday, bringing an end to the heat event," the weather agency said in a statement on Monday morning. The heat warning is in effect for the following areas: Toronto, Mississauga, Brampton, Vaughan, Richmond Hill, Markham, Durham Region, Newmarket, Georgina, Halton Hills, Milton and Oshawa. People are advised to drink water often, watch for signs of heat exhaustion and to check on those at-risk for heat illnesses, said the weather agency. It also suggests wearing light-colored clothing and limiting exposure to the heat. Signs of heat stroke can include red and hot skin, dizziness and nausea. Over 500 spaces across Toronto are available for residents looking for relief during a heat warning, including the following air-conditioned facilities: North York Civic Centre Scarborough Civic Centre Etobicoke Civic Centre York Civic Centre East York Community Centre Metro Hall lobby The buildings will be open until 9:30 p.m. every day that a warning is in effect, with the exception of the Metro Hall lobby which is open 24 hours a day.